Alzamend Neuro Inc (ALZN)
Alzamend Neuros Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Alzamend Neuros Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial